Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 200

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 200
---
 of common stock as reported on the date of issuance of the Class F Common Stock Warrants based on the alternative cashless exercise provision issued in connection with the Class E Warrant Inducement are treated as equity and the Company recognized approximately $4.1 million as a non -cashequity issuance cost netted against the additional paid -incapital. Additionally, using the Black -Scholesoption pricing model, the Class G Common Stock Warrants issued in connection with the Class E Warrant Inducement are treated as equity and the Company recognized approximately $2.1 million as a non -cashequity issuance cost netted against the additional paid -incapital (see Note 10). Total cash and non -cashequity issuance costs recognized in the Class F Common Stock Warrants and the Class G Common Stock Warrants of $6.5 million include cash equity issuance costs of $0.4 million and non -cashequity issuance costs of approximately $6.2 million. As of December 31, 2024, there are 1,032,080 Class E Common Stock Warrants outstanding to purchase 64,506shares of common stock that were not included in the Class E Warrant Inducement. As part of the 2025 Reverse Stock Split on January 28, 2025, the number of shares of common stock the Class G Common Stock Warrants are exercisable into was reset from 381,004 to 1,621,463 and the exercise price of the Class G Common Stock Warrants was reset from $16.00 to $3.7596. F-16 REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 7. Preferred Stock Revelation Authorized Preferred Stock The Company is authorized under its articles of incorporation, as amended, up to 5,000,000shares of preferred stock, which may be issued as designated by the Board of Directors without stockholder approval. As of December 31, 2024 and as of the date of this Report, there were no shares of preferred stock issued and outstanding. Series A Preferred Stock On December 19, 2022, the Company closed the sale of one share of the Company’s Series A Preferred Stock, par value $0.001 per share, to its Chief Executive Officer for $5,000.00. The outstanding share of Series A Preferred Stock was automatically redeemed for $5,000.00 on January 30, 2023 upon the